The Chloroquine for Influenza Prevention Trial

A Randomised, Double-blind, Placebo Controlled Trial of Chloroquine for the Prevention of Influenza

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01078779

Acronym

CHIP

Enrollment

1516

Registered

2010-03-02

Start date

2009-11-30

Completion date

2010-08-31

Last updated

2010-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

Influenza, Prevention, Chloroquine, Randomised controlled trial, Respiratory virus infection

Brief summary

A randomised controlled trial to determine the efficacy of chloroquine for the prevention of influenza

Interventions

DRUGChloroquine

Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks

DRUGPlacebo

Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 18 -65 * Have the ability to provide informed consent * If a woman of child-bearing potential, willing to use contraception for the period of the trial

Exclusion criteria

* Acute influenza-like illness at screening * History of psoriasis, porphyria cutanea tarda, epilepsy, myasthenia gravis, myopathy of any cause, cardiac arrhythmias, or serious hepatic or renal disease * Pregnancy or breast feeding * Current use of medication with known serious hepatotoxic effects * Current use of medication with known serious interaction with CQ: amiodarone, anticonvulsants, ciclosporin, digoxin, mefloquine, moxifloxacin * Current severe depression (as indicated by current use of antidepressant medication) * Known serious retinal disease * Current or recent (within the past 30 days) participation in any other clinical intervention trial. * Known G6PD deficiency * Vaccination for influenza (seasonal or H1N1 strain) within the 3 months prior to screening

Design outcomes

Primary

Measure	Time frame
Laboratory-confirmed influenza-like illness	12 weeks

Secondary

Measure	Time frame	Description
Serologically-confirmed influenza infection (symptomatic or asymptomatic)	12 weeks	Four-fold rise in influenza antibody titre at week 12 compared to the baseline sample

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026